Vascular Intervention Giant Cordis Reportedly Up for Sale Again: From J&J Divestiture to 9-Fold Valuation Surge in Four Years
Johnson & Johnson
Medical Device R&D and Manufacturer
On January 17, according to a report by Bloomberg citing informed sources:U.S. private equity firm Hellman & FriedmanFor SaleMedical device manufacturer Cordis (ConTis）Preliminary negotiations, Cordis valuationMore than 9 billion US dollars。
The report claims that currently there are approximatelySix CompaniesListed medical device companies are evaluating potential acquisition options for Cordis.
CordisFounded in 1957，Focus on Coronary Intervention and Peripheral Intervention FieldsField,Is globalOne of the leading vascular intervention enterprises.
It consists of three main departments:Cardiovascular Intervention Products Department、Peripheral Vascular and Neurointerventional DepartmentAndBiosense WebsterSince its inception, Cordis has developed and launched several groundbreaking products in the industry, such as the Judkins catheter, the S.M.A.R.T self-expanding stent made of nickel-titanium alloy, and the Cypher coronary drug-eluting stent. These products quickly became "industry standards," revolutionized traditional surgical methods, and established Cordis as a pioneer in the vascular intervention field.
Cordis joined in 1996Johnson & Johnson, but since Johnson & Johnson discontinued Cypher in 2011, Cordis has gradually become a non-core asset.
In 2015, Johnson & Johnson$1.944 billionCordis was sold toCardinal Health(Cardinal Health), but eventually in 2021,Cardinal Health$1 billionPrice for SaleToH＆F，Value Shrinks by Nearly Half。
H&F Accelerates After Taking OverCordis Innovation，August 2021，ConTisOfficially become an independent company,Entering the fast development track:
In April 2022, the business scope was expanded to the venous thromboembolism market (VTM) through an investment in Endovascular Engineering (E2).
In June 2022, collaborated with Adient Medical Investment to develop a new generation of absorbable inferior vena cava filter;
In October 2022, MedAlliance, a Swiss medical technology company, was acquired for $1.135 billion (approximately RMB 8 billion). Through this acquisition, CORDIS expects to provide the SELUTION SLR drug-coated balloon to two million patients globally by 2027. In February 2023, invested in Puzzle Medical Devices,Develop a long-term interventional heart pump, ModulHeart, for patients with advanced heart failure.
